Conference Track

Breast Cancer

Source: CCO Independent Conference Coverage of the 2008 American Society of Clinical Oncology Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Adjuvant Zoledronic Acid Significantly Improves DFS in Premenopausal Women With Endocrine-Responsive Breast Cancer
Addition of Gemcitabine to Paclitaxel following Adjuvant Epirubicin and Cyclophosphamide (EC-GT) Does Not Improve Survival in Early-Stage Breast Cancer
Superior Relapse-Free and Overall Survival With Standard Adjuvant Chemotherapy Compared to Capecitabine in Older Breast Cancer Patients
Early-Stage Breast Cancer Patients More Likely to Undergo Mastectomy With Preoperative Breast MRI
Vitamin D Deficiency Associated With Increased Risk of Disease Recurrence and Death in Newly Diagnosed Breast Cancer
Zoledronic Acid Shown to Prevent Bone Loss in Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure
Adjuvant Tamoxifen Continued Beyond 5 Years May Not Significantly Reduce Risk of Breast Cancer Recurrence
Molecular Phenotype of Relapsed Tumor Differs From Primary Tumor in Subset of Patients With Relapsed/Metastatic Breast Cancer
AVADO Phase III Trial Results: Adding Bevacizumab to First-Line Docetaxel Benefits Patients With HER2-Negative Metastatic Breast Cancer
Lapatinib Plus Trastuzumab Improves PFS and Response Rate vs Lapatinib Alone in Progressive HER2-Positive Metastatic Breast Cancer
Lapatinib Plus Pazopanib Combination Shows Greater Activity Than Lapatinib Alone as First-Line Treatment of HER2-Positive Advanced or Metastatic Breast Cancer
Continued Trastuzumab Potentiates Capecitabine Activity After Disease Progression in Metastatic and Locally Advanced HER2-Positive Breast Cancer

Expert Analysis

Breast Cancer Panel

Program Director: Ramaswamy Govindan, MD

Faculty:

William J. Gradishar, MD, FACP
Clifford A. Hudis, MD
Kathy D. Miller, MD

Christy Russell, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data from recent studies regarding current standards of care for the use of tamoxifen
Describe new data on the use of the investigational agents pertuzumab and pazopanib in the treatment of patients with HER2-positive metastatic breast cancer
Discuss the integration of treatment strategies involving multiple agents for the clinical management of patients with breast cancer

CME CREDIT INFORMATION

Release Date: 08/07/08

Expiration Date: 08/06/09

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.